Table 1.

Clinical cases of abscopal effect after RT with immunotherapy according to the search criteria

Study	Year	Age (yr)/Sex	Primary tumor	RT dose (Gy)	Immunotherapy	Site of abscopal effect	Time (mo)
Wersall et al. [21]	2006	64/F	Kidney	NA	Interferon, interleukin-2	Lung	13
Stamell et al. [22]	2012	67/M	Melanoma	24 × 3	Ipilimumab	LN	N/A
Postow et al. [23]	2012	33/F	Melanoma	28.5	Ipilimumab	Lung	4
Hiniker et al. [24]	2012	57/M	Melanoma	54 × 3	Ipilimumab	Liver, LN	6
		57/M	Melanoma	54	Ipilimumab	Liver	4
Golden et al. [25]	2013	64/M	Lung	30	Ipilimumab	Lung, liver, bones	NA
Kodama et al. [26]	2014	74/M	Lung	58 × 29	Bcg-vaccine	Lung	6
Grimaldi et al. [27]	2014	NA	Melanoma	30 × 10	Ipilimumab	Liver	1
		NA	Melanoma	30 × 10	Ipilimumab	Pelvic	1
		NA	Melanoma	50 × 25	Ipilimumab	Liver, derma	4
		NA	Melanoma	20 × 5	Ipilimumab	Intestines, derma, lung, LN	1
		NA	Melanoma	30 × 10	Ipilimumab	Liver, ovary	1
		NA	Melanoma	30 × 10	Ipilimumab	Lung, derma, LN	3
		NA	Melanoma	30 × 10	Ipilimumab	Derma, sternum, LN	1
		NA	Melanoma	30 × 10	Ipilimumab	Lung	1
		NA	Melanoma	24	Ipilimumab	Derma	1
		NA	Melanoma	20	Ipilimumab	Liver	2
		NA	Melanoma	24	Ipilimumab	Lung	1
Michot et al. [28]	2016	33/M	Lymphoma	30	Pembrolizumab	LN	2
Cong et al. [29]	2017	64/F	Lung	37.5	Dendritic cells, cytokine killers	Lung	10
Shi et al. [30]	2017	67/F	Pancreatic	45	Granulocyte-macrophage colony stimulating factor	Liver	1
LaPlant et al. [31]	2017	24/F	Kidney	27	Ipilimumab	Lung, LN	7
Sato et al. [32]	2017	54/M	Stomach	48	Т-cells, dendritic cells	Abdomen	2
Britschgi et al. [33]	2018	47/M	Lung	18	Nivolumab	LN	3
Tsui et al. [34]	2018	65/F	Melanoma	24	Nivolumab	Lung	NA
Zhao et al. [35]	2018	65/M	Esophagus	42	Pembrolizumab	LN	2
Rodriguez-Ruiz et al. [36]	2018	68/M	Prostate	24	Dendritic cells, hiltonol	Lung	3

RT, radiation therapy; LN, lymph node; NA, not applicable.